Audrey Tluczek1, Tara Becker2, Anita Laxova3, Adam Grieve3, Caroline N Racine Gilles3, Michael J Rock3, William M Gershan4, Christopher G Green3, Philip M Farrell3. 1. School of Nursing, School of Medicine and Public Health, University of Wisconsin, Madison, WI; Department of Pediatrics Racine, School of Medicine and Public Health, University of Wisconsin, Madison, WI. Electronic address: atluczek@wisc.edu. 2. Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison. 3. Department of Pediatrics Racine, School of Medicine and Public Health, University of Wisconsin, Madison, WI. 4. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
Abstract
BACKGROUND: The objective of this study was to examine relationships between pulmonary health and health-related quality of life (HRQOL) in patients with cystic fibrosis (CF) evaluated longitudinally in the Wisconsin Newborn Screening Project. METHODS: Patients aged 8 to 18 years (mean ± SD, 13.5 ± 2.8) in early diagnosis (n = 45) and control (n = 50) groups completed Cystic Fibrosis Questionnaires (CFQs) to measure HRQOL at three data points over a 2-year period. Pulmonary health was evaluated concurrently by the Wisconsin chest x-ray scoring system (WCXR) and pulmonary function tests (PFTs). RESULTS: WCXR showed significant group differences (P ≤ .023), with the early diagnosis group showing more-severe lung disease. When adjusted for group differences in mucoid Pseudomonas aeruginosa status and pancreatic status, however, WCXR differences and PFT data were not significant. Most patients (74%) had FEV(1) values ≥ 80% predicted (within normal range). For patients aged < 14 years, as WCXR scores worsened CFQ respiratory and physical domain scores decreased (both P ≤ .007). FEV(1)/FVC showed a positive relationship with the respiratory and physical domains (both P ≤ .006). WCXR scores for patients aged ≥ 14 years were associated with CFQ weight, respiratory, and health domains (all P ≤ .011). FEV(1) was associated with CFQ weight, respiratory, health, and physical domains (all P ≤ .003). Changes in pulmonary health were not associated with changes in CFQ over time. Significant group differences on the CFQ-Child social functioning domain favored the control group. CONCLUSIONS: To our knowledge, this study is the first to compare pulmonary outcomes with HRQOL indicators assessed by serial, standardized, patient-reported outcome measures for patients with CF identified either through newborn screening or diagnosed by use of traditional methods. This study found no benefits of newborn screening for pulmonary health or HRQOL after controlling for risk factors. Using WCXR and PFT data collectively helped to identify associations between pulmonary health and HRQOL.
BACKGROUND: The objective of this study was to examine relationships between pulmonary health and health-related quality of life (HRQOL) in patients with cystic fibrosis (CF) evaluated longitudinally in the Wisconsin Newborn Screening Project. METHODS:Patients aged 8 to 18 years (mean ± SD, 13.5 ± 2.8) in early diagnosis (n = 45) and control (n = 50) groups completed Cystic Fibrosis Questionnaires (CFQs) to measure HRQOL at three data points over a 2-year period. Pulmonary health was evaluated concurrently by the Wisconsin chest x-ray scoring system (WCXR) and pulmonary function tests (PFTs). RESULTS: WCXR showed significant group differences (P ≤ .023), with the early diagnosis group showing more-severe lung disease. When adjusted for group differences in mucoid Pseudomonas aeruginosa status and pancreatic status, however, WCXR differences and PFT data were not significant. Most patients (74%) had FEV(1) values ≥ 80% predicted (within normal range). For patients aged < 14 years, as WCXR scores worsened CFQ respiratory and physical domain scores decreased (both P ≤ .007). FEV(1)/FVC showed a positive relationship with the respiratory and physical domains (both P ≤ .006). WCXR scores for patients aged ≥ 14 years were associated with CFQ weight, respiratory, and health domains (all P ≤ .011). FEV(1) was associated with CFQ weight, respiratory, health, and physical domains (all P ≤ .003). Changes in pulmonary health were not associated with changes in CFQ over time. Significant group differences on the CFQ-Child social functioning domain favored the control group. CONCLUSIONS: To our knowledge, this study is the first to compare pulmonary outcomes with HRQOL indicators assessed by serial, standardized, patient-reported outcome measures for patients with CF identified either through newborn screening or diagnosed by use of traditional methods. This study found no benefits of newborn screening for pulmonary health or HRQOL after controlling for risk factors. Using WCXR and PFT data collectively helped to identify associations between pulmonary health and HRQOL.
Authors: R E Koscik; M R Kosorok; P M Farrell; J Collins; M E Peters; A Laxova; C G Green; L Zeng; L S Rusakow; R C Hardie; P W Campbell; J W Gurney Journal: Pediatr Pulmonol Date: 2000-06
Authors: Christopher M Oermann; George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Karen S McCoy; A Bruce Montgomery; Peter J Cooper Journal: Pediatr Pulmonol Date: 2010-11
Authors: P M Farrell; M R Kosorok; M J Rock; A Laxova; L Zeng; H C Lai; G Hoffman; R H Laessig; M L Splaingard Journal: Pediatrics Date: 2001-01 Impact factor: 7.124
Authors: Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: Philip M Farrell; Zhanhai Li; Michael R Kosorok; Anita Laxova; Christopher G Green; Jannette Collins; Hui-Chuan Lai; Michael J Rock; Mark L Splaingard Journal: Am J Respir Crit Care Med Date: 2003-08-13 Impact factor: 21.405
Authors: Philip M Farrell; Zhanhai Li; Michael R Kosorok; Anita Laxova; Christopher G Green; Jannette Collins; Hui-Chuan Lai; Linda M Makholm; Michael J Rock; Mark L Splaingard Journal: Pediatr Pulmonol Date: 2003-09
Authors: Audrey Tluczek; Anita Laxova; Adam Grieve; Anne Heun; Roger L Brown; Michael J Rock; William M Gershan; Philip M Farrell Journal: J Cyst Fibros Date: 2013-10-21 Impact factor: 5.482
Authors: Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell Journal: Ann Am Thorac Soc Date: 2014-01
Authors: Audrey Tluczek; Tara Becker; Adam Grieve; Anita Laxova; Michael J Rock; William M Gershan; Christopher G Green; Philip M Farrell Journal: J Dev Behav Pediatr Date: 2013-05 Impact factor: 2.225
Authors: Christina B Barreda; Philip M Farrell; Anita Laxova; Jens C Eickhoff; Andrew T Braun; Ryan J Coller; Michael J Rock Journal: J Cyst Fibros Date: 2020-06-13 Impact factor: 5.482